Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials
Michele Fornaro,1,2 Marco Solmi,3–5 Giampaolo Perna,2,6 Domenico De Berardis,2,7 Nicola Veronese,5,8 Laura Orsolini,2,9 Licinia Ganança,1,10 Brendon Stubbs11,12 1New York State Psychiatric Institute, Columbia University, New York City, NY, USA; 2Polyedra Research Group&...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-07-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/lisdexamfetamine-in-the-treatment-of-moderate-to-severe-binge-eating-d-peer-reviewed-fulltext-article-NDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849424725658304512 |
|---|---|
| author | Fornaro M Solmi M Perna G De Berardis D Veronese N Orsolini L Ganança L Stubbs B |
| author_facet | Fornaro M Solmi M Perna G De Berardis D Veronese N Orsolini L Ganança L Stubbs B |
| author_sort | Fornaro M |
| collection | DOAJ |
| description | Michele Fornaro,1,2 Marco Solmi,3–5 Giampaolo Perna,2,6 Domenico De Berardis,2,7 Nicola Veronese,5,8 Laura Orsolini,2,9 Licinia Ganança,1,10 Brendon Stubbs11,12 1New York State Psychiatric Institute, Columbia University, New York City, NY, USA; 2Polyedra Research Group®, Ascoli, 3Department of Neurosciences, University of Padua, 4Department of Mental Health, National Health Service, Padova, 5IREM Institute for Clinical Research and Education in Medicine, Padova, 6Department of Clinical Neurosciences, Hermanas Hospitalarias – Villa San Benedetto Menni Hospital, FoRiPsi, Albese con Cassano, Como, 7Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, National Health Service, Hospital “G Mazzini”, Teramo, 8Department of Medicine (DIMED), University of Padua, Padova, Italy; 9Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK; 10Department of Psychiatry, School of Medicine, University of Lisbon, Lisbon, Portugal; 11Department of Health Service and Population Research, Institute of Psychiatry, King’s College London, 12Department of Physiotherapy, South London and Maudsley NHS Foundation Trust, London, UK Background: Preliminary placebo-controlled evidence paved the ground to the US Food and Drug Administration approval extension of lisdexamfetamine for the treatment of moderate-to-severe binge eating disorder (BED) in adults.Objectives: To provide a preliminary qualitative and quantitative synthesis of the placebo-controlled, randomized clinical trials (RCTs) considering the efficacy and tolerability of lisdexamfetamine in the acute and/or maintenance treatment of moderate-to-severe BED in adults.Methods: A preliminary, yet comprehensive, systematic review was performed by accessing a broad range of resources providing publicly available data about lisdexamfetamine at the time of inquiry (March 2016). Study eligibility criteria, participants, and interventions were considered focusing on major clinical and functional outcomes of either efficacy or tolerability of lisdexamfetamine in the treatment of moderate-to-severe BED in adults.Results: Meta-analysis of data pooled from three acute RCTs significantly favored lisdexamfetamine over placebo in the reduction of binge eating days/week, Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating total score, weight, response, and remission rates (all, P≤0.01). In contrast, discontinuation rates due to treatment-emergent adverse events were significantly higher among patients in receipt of lisdexamfetamine (relative risk 2.19, P=0.04) versus placebo.Limitations: Publication, selection, performance, attrition, reporting, sponsorship, and “diagnostic shift” biases. Lack of inclusion of adverse event effects other than those requiring discontinuation of the trial(s), as well as lack of information about clinically relevant psychiatric or other medical comorbidities, limits the overall generalizability of pooled results.Conclusion: Across the included acute phase RCTs, lisdexamfetamine (at 30, 50, or 70 mg/day) led to significant reduction in a number of clinically relevant outcomes compared to placebo. Moreover, safety concerns related to adverse events, high discontinuation rates, and the need for additional long-term maintenance of RCTs solicit careful monitoring of the drug in terms of overall safety and tolerability by further RCTs. Keywords: lisdexamfetamine, binge eating disorder, systematic review, meta-analysis |
| format | Article |
| id | doaj-art-fe4e9f795d7748e4a9c8a71ec9cc1628 |
| institution | Kabale University |
| issn | 1178-2021 |
| language | English |
| publishDate | 2016-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj-art-fe4e9f795d7748e4a9c8a71ec9cc16282025-08-20T03:30:03ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212016-07-01Volume 12Issue 11827183628062Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trialsFornaro M0Solmi MPerna GDe Berardis D1Veronese NOrsolini LGanança LStubbs BDept of Psychiatry Mol ImagingDepartment of Mental Health, Psychiatric Service of Diagnosis & TreatmentMichele Fornaro,1,2 Marco Solmi,3–5 Giampaolo Perna,2,6 Domenico De Berardis,2,7 Nicola Veronese,5,8 Laura Orsolini,2,9 Licinia Ganança,1,10 Brendon Stubbs11,12 1New York State Psychiatric Institute, Columbia University, New York City, NY, USA; 2Polyedra Research Group®, Ascoli, 3Department of Neurosciences, University of Padua, 4Department of Mental Health, National Health Service, Padova, 5IREM Institute for Clinical Research and Education in Medicine, Padova, 6Department of Clinical Neurosciences, Hermanas Hospitalarias – Villa San Benedetto Menni Hospital, FoRiPsi, Albese con Cassano, Como, 7Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, National Health Service, Hospital “G Mazzini”, Teramo, 8Department of Medicine (DIMED), University of Padua, Padova, Italy; 9Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK; 10Department of Psychiatry, School of Medicine, University of Lisbon, Lisbon, Portugal; 11Department of Health Service and Population Research, Institute of Psychiatry, King’s College London, 12Department of Physiotherapy, South London and Maudsley NHS Foundation Trust, London, UK Background: Preliminary placebo-controlled evidence paved the ground to the US Food and Drug Administration approval extension of lisdexamfetamine for the treatment of moderate-to-severe binge eating disorder (BED) in adults.Objectives: To provide a preliminary qualitative and quantitative synthesis of the placebo-controlled, randomized clinical trials (RCTs) considering the efficacy and tolerability of lisdexamfetamine in the acute and/or maintenance treatment of moderate-to-severe BED in adults.Methods: A preliminary, yet comprehensive, systematic review was performed by accessing a broad range of resources providing publicly available data about lisdexamfetamine at the time of inquiry (March 2016). Study eligibility criteria, participants, and interventions were considered focusing on major clinical and functional outcomes of either efficacy or tolerability of lisdexamfetamine in the treatment of moderate-to-severe BED in adults.Results: Meta-analysis of data pooled from three acute RCTs significantly favored lisdexamfetamine over placebo in the reduction of binge eating days/week, Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating total score, weight, response, and remission rates (all, P≤0.01). In contrast, discontinuation rates due to treatment-emergent adverse events were significantly higher among patients in receipt of lisdexamfetamine (relative risk 2.19, P=0.04) versus placebo.Limitations: Publication, selection, performance, attrition, reporting, sponsorship, and “diagnostic shift” biases. Lack of inclusion of adverse event effects other than those requiring discontinuation of the trial(s), as well as lack of information about clinically relevant psychiatric or other medical comorbidities, limits the overall generalizability of pooled results.Conclusion: Across the included acute phase RCTs, lisdexamfetamine (at 30, 50, or 70 mg/day) led to significant reduction in a number of clinically relevant outcomes compared to placebo. Moreover, safety concerns related to adverse events, high discontinuation rates, and the need for additional long-term maintenance of RCTs solicit careful monitoring of the drug in terms of overall safety and tolerability by further RCTs. Keywords: lisdexamfetamine, binge eating disorder, systematic review, meta-analysishttps://www.dovepress.com/lisdexamfetamine-in-the-treatment-of-moderate-to-severe-binge-eating-d-peer-reviewed-fulltext-article-NDTLisdexamfetaminebinge eating disordersystematic-reviewmeta-analysis. |
| spellingShingle | Fornaro M Solmi M Perna G De Berardis D Veronese N Orsolini L Ganança L Stubbs B Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials Neuropsychiatric Disease and Treatment Lisdexamfetamine binge eating disorder systematic-review meta-analysis. |
| title | Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials |
| title_full | Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials |
| title_fullStr | Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials |
| title_full_unstemmed | Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials |
| title_short | Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials |
| title_sort | lisdexamfetamine in the treatment of moderate to severe binge eating disorder in adults systematic review and exploratory meta analysis of publicly available placebo controlled randomized clinical trials |
| topic | Lisdexamfetamine binge eating disorder systematic-review meta-analysis. |
| url | https://www.dovepress.com/lisdexamfetamine-in-the-treatment-of-moderate-to-severe-binge-eating-d-peer-reviewed-fulltext-article-NDT |
| work_keys_str_mv | AT fornarom lisdexamfetamineinthetreatmentofmoderatetoseverebingeeatingdisorderinadultssystematicreviewandexploratorymetaanalysisofpubliclyavailableplacebocontrolledrandomizedclinicaltrials AT solmim lisdexamfetamineinthetreatmentofmoderatetoseverebingeeatingdisorderinadultssystematicreviewandexploratorymetaanalysisofpubliclyavailableplacebocontrolledrandomizedclinicaltrials AT pernag lisdexamfetamineinthetreatmentofmoderatetoseverebingeeatingdisorderinadultssystematicreviewandexploratorymetaanalysisofpubliclyavailableplacebocontrolledrandomizedclinicaltrials AT deberardisd lisdexamfetamineinthetreatmentofmoderatetoseverebingeeatingdisorderinadultssystematicreviewandexploratorymetaanalysisofpubliclyavailableplacebocontrolledrandomizedclinicaltrials AT veronesen lisdexamfetamineinthetreatmentofmoderatetoseverebingeeatingdisorderinadultssystematicreviewandexploratorymetaanalysisofpubliclyavailableplacebocontrolledrandomizedclinicaltrials AT orsolinil lisdexamfetamineinthetreatmentofmoderatetoseverebingeeatingdisorderinadultssystematicreviewandexploratorymetaanalysisofpubliclyavailableplacebocontrolledrandomizedclinicaltrials AT ganancal lisdexamfetamineinthetreatmentofmoderatetoseverebingeeatingdisorderinadultssystematicreviewandexploratorymetaanalysisofpubliclyavailableplacebocontrolledrandomizedclinicaltrials AT stubbsb lisdexamfetamineinthetreatmentofmoderatetoseverebingeeatingdisorderinadultssystematicreviewandexploratorymetaanalysisofpubliclyavailableplacebocontrolledrandomizedclinicaltrials |